Cialis(tadalafil)
Adcirca, Alyq, Cialis, Entadfi, Tadliq (tadalafil) is a small molecule pharmaceutical. Tadalafil was first approved as Cialis on 2002-11-12. It is used to treat pulmonary hypertension and vasculogenic impotence in the USA. It has been approved in Europe to treat erectile dysfunction and pulmonary hypertension. The pharmaceutical is active against cGMP-specific 3',5'-cyclic phosphodiesterase. In addition, it is known to target dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Adcirca, Alyq, Cialis, Tadliq (generic drugs available since 2018-05-22)
CombinationsEntadfi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Finasteride
+
Tadalafil
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENTADFI | Veru | N-215423 RX | 2021-12-09 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
| vasculogenic impotence | EFO_1001234 | D018783 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Tadalafil, Tadliq, Cmp Dev Llc | |||
| 11382917 | 2038-12-24 | DP | U-3397 |
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02K: Other antihypertensives in atc
— C02KX: Antihypertensives for pulmonary arterial hypertension
— C02KX52: Ambrisentan and tadalafil
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BE: Drugs used in erectile dysfunction
— G04BE08: Tadalafil
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA54: Tamsulosin and tadalafil
HCPCS
No data
Clinical
Clinical Trials
203 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 4 | 5 | 21 | 19 | 12 | 61 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 6 | 5 | 13 | 3 | 2 | 28 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | 3 | 8 | 3 | — | 14 |
| Pulmonary arterial hypertension | D000081029 | 2 | 2 | 2 | 7 | 1 | 13 | ||
| Healthy volunteers/patients | — | 8 | 1 | — | 1 | — | 10 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 1 | 3 | — | 5 |
| Duchenne muscular dystrophy | D020388 | 2 | 1 | 2 | 1 | — | 5 | ||
| Premature ejaculation | D061686 | HP_0012876 | F52.4 | — | — | 3 | 1 | — | 4 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | 2 | 2 | 4 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 1 | — | 1 | — | 3 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | — | 1 | 3 | — | — | 4 | |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | 2 | — | — | 3 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | 2 | — | 1 | 3 |
| Interstitial lung diseases | D017563 | EFO_0004244 | J84.89 | — | — | 1 | — | — | 1 |
| Psychological sexual dysfunctions | D020018 | F52.0 | — | — | 1 | — | — | 1 | |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | 1 | — | — | 1 | |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | 1 | — | — | 1 |
| Fontan procedure | D018729 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma of head and neck | D000077195 | 1 | 3 | — | — | — | 4 | ||
| Head and neck neoplasms | D006258 | 1 | 1 | — | — | 1 | 3 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 2 | — | — | 1 | 3 |
| Pulmonary edema | D011654 | EFO_1001134 | J81 | 1 | 1 | — | — | 1 | 2 |
| Cerebral small vessel diseases | D059345 | — | 2 | — | — | — | 2 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | 2 | 2 | — | — | — | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 2 | 2 | — | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | 1 | 2 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 2 | — | — | — | 2 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | 1 | — | — | — | — | 1 | |
| Astrocytoma | D001254 | EFO_0000271 | 1 | — | — | — | — | 1 | |
| Smoking | D012907 | EFO_0003768 | F17 | 1 | — | — | — | — | 1 |
| Abdominal neoplasms | D000008 | 1 | — | — | — | — | 1 | ||
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | 1 | — | — | — | — | 1 |
| Stress urinary incontinence | D014550 | HP_0010992 | 1 | — | — | — | — | 1 | |
| Fecal incontinence | D005242 | R15 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | — | 2 | 2 |
| Prostatitis | D011472 | EFO_0003830 | N41 | — | — | — | — | 1 | 1 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Brain edema | D001929 | EFO_1000845 | G93.6 | — | — | — | — | 1 | 1 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TADALAFIL |
| INN | tadalafil |
| Description | Tadalafil is a pyrazinopyridoindole that is 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione substituted at position 2 by a methyl group and at position 6 by a 1,3-benzodioxol-5-yl group (the 6R,12aR-diastereomer). A phosphodiesterase V inhibitor inhibitor, currently marketed in pill form for treating erectile dysfunction under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension. It has a role as an EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor and a vasodilator agent. It is a pyrazinopyridoindole and a member of benzodioxoles. |
| Classification | Small molecule |
| Drug class | phosphodiesterase type 5 inhibitors (PDE5) inhibitors: (PDE5) inhibitors containing a sulfonamide moiety |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O |
Target
Agency Approved
PDE5A
PDE5A
Organism
Homo sapiens
Gene name
PDE5A
Gene synonyms
PDE5
NCBI Gene ID
Protein name
cGMP-specific 3',5'-cyclic phosphodiesterase
Protein synonyms
CGB-PDE, cGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase, cGMP-binding cGMP-specific phosphodiesterase, cGMP-specific phosphodiesterase PDE5A2, cGMP-specific phosphodiesterase type 5A, phosphodiesterase 5A, cGMP-specific, phosphodiesterase isozyme 5
Uniprot ID
Mouse ortholog
Pde5a (242202)
cGMP-specific 3',5'-cyclic phosphodiesterase (Q8CG03)
Alternate
PDE11A
PDE11A
Organism
Homo sapiens
Gene name
PDE11A
Gene synonyms
NCBI Gene ID
Protein name
dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
Protein synonyms
cAMP and cGMP cyclic nucleotide phosphodiesterase 11A, cAMP and cGMP phosphodiesterase 11A
Uniprot ID
Mouse ortholog
Pde11a (241489)
dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A (P0C1Q2)
Variants
Clinical Variant
No data
Financial
Cialis - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Entadfi - VERU INC.
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Adcirca - United Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,620 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
47,045 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more